CMS Modified NCD 143 for Transfer Factor in Multiple Sclerosis Treatment — What Billing Teams Need to Know in 2026

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 143, the national coverage determination governing transfer factor as a treatment for multiple sclerosis, effective March 7, 2026. The policy maintains its non-coverage position — transfer factor remains excluded from Medicare reimbursement for MS treatment on experimental grounds.

The CMS transfer factor coverage policy under NCD 143 hasn't opened any new doors for billing teams. This is a modified policy, not a new one, and the core determination hasn't shifted: transfer factor for multiple sclerosis is still not covered. If you've been watching this policy waiting for a change in coverage status, this update isn't it.

Quick-Reference Table

CMS Transfer Factor Multiple Sclerosis Coverage Criteria and Medical Necessity Requirements 2026

NCD 143 is the National Coverage Determination governing Medicare coverage of transfer factor when used to treat multiple sclerosis. Under this policy, transfer factor does not meet medical necessity criteria for MS treatment. That hasn't changed with this modification.

Transfer factor is the dialysate of an extract from sensitized leukocytes. It increases cellular immune activity in the recipient. The clinical rationale makes some intuitive sense — MS involves immune dysregulation, and transfer factor affects the immune system. But CMS has determined that the evidence isn't there to support coverage.

The explicit language from the policy is unambiguous: transfer factor "is not covered as a treatment for multiple sclerosis because its use for this purpose is still experimental." CMS does not recognize a covered indication for this service under this national coverage determination.

The benefit category under which this policy falls is "incident to a physician's professional service." That framing matters. It means this isn't a standalone procedure coverage question — it sits within the context of physician-directed care. Even so, the non-coverage determination applies regardless of how the service is billed or who supervises it.

Whether transfer factor is covered under Medicare for MS patients is a settled question under this policy: it is not. No amount of prior authorization documentation, medical necessity letters, or appeals framing will change that. NCD 143 in the CMS system is a national-level determination, which means it preempts any local coverage determination a Medicare Administrative Contractor might otherwise issue for this service.

CMS Transfer Factor Exclusions and Non-Covered Indications

The entire basis of NCD 143 is a non-coverage determination. There are no covered indications for transfer factor in multiple sclerosis under Medicare. None.

CMS classifies this use as experimental. That's a specific and significant designation in Medicare billing. Experimental means the service doesn't meet the evidentiary threshold for routine Medicare coverage — regardless of what a treating physician believes about its clinical value.

The real issue here is what "experimental" means for your claim. When CMS labels a treatment experimental under an NCD, you cannot successfully bill Medicare for that service. The claim will deny. An Advance Beneficiary Notice of Noncoverage (ABN) may allow you to bill the patient directly, but Medicare reimbursement is off the table.

If your practice has been exploring transfer factor as part of an MS treatment protocol and considering Medicare billing, stop that process now. The experimental designation under NCD 143 is the controlling authority. There's no pathway to Medicare reimbursement here through standard claims processes.

Some providers confuse experimental NCD exclusions with situations where a prior authorization might unlock coverage. It won't here. A prior auth request for a service designated experimental under a national coverage determination will be denied at the prior authorization stage — before a claim is even submitted.

Coverage Indications at a Glance

CMS Transfer Factor Billing Guidelines and Action Items 2026

The policy doesn't create new billing complexity — it reinforces an existing wall. But that doesn't mean your billing team has nothing to do. Here's what to act on before and after the March 7, 2026 effective date.

CPT, HCPCS, and ICD-10 Codes for Transfer Factor in Multiple Sclerosis Under NCD 143

A Note on Missing Codes

NCD 143 does not list specific CPT or HCPCS codes. This is worth flagging directly — not burying. The absence of codes in the policy creates a real-world billing problem: your team has to identify which codes in your system map to transfer factor services and apply the non-coverage logic manually.

CMS billing guidelines in NDCs occasionally omit procedure codes when the service predates modern code sets or when the service is so narrowly defined that CMS defers to local MAC-level coding guidance. This appears to be one of those situations.

What This Means for Your Charge Capture

Without a code list in the NCD, you can't build a simple claim-edit rule off the policy itself. You need to work backward from your own coding practices.

Talk to your coding team and identify any codes you currently use — or have used — to bill transfer factor services. Then apply the NCD 143 non-coverage determination to those codes in your Medicare billing rules. If you're unsure how to map this, your MAC's provider relations line or a billing consultant familiar with immunology coding is your best resource.

No Covered Codes Under This Policy

There are no covered CPT, HCPCS, or ICD-10 codes to list for this service under NCD 143. The policy is a blanket non-coverage determination with no covered indications and no code-specific exceptions. Any code your practice uses to bill transfer factor for MS treatment to Medicare falls under this non-coverage determination.